Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Justine E Marum, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Martin C. Mueller, Christian T. Dietz, PhD, Ieuan Walker, MSc, BSc, MBBS, Nathalie Nataren, BSc, Zoe Donaldson, BSc, Wendy T Parker, PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Andreas W Schreiber, PhD, Susan Branford, PhD FFSc (RCPA)

Blood (2016) 128 (22): 1219.

https://doi.org/10.1182/blood.V128.22.1219.1219

Published: 2016

Journal Articles

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Verity A Saunders, BSc (Hons), Jueqiong Wang, PhD, Liu Lu, PhD, Laura N Eadie, PhD, Jennifer A McLean, Jarrad M Goyne, BMedSc (Hons), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1121.

https://doi.org/10.1182/blood.V128.22.1121.1121

Published: 2016

Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD

Blood (2016) 128 (22): 5447.

https://doi.org/10.1182/blood.V128.22.5447.5447

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

Naranie Shanmuganathan, MBBS, FRACP, FRCPA, Susan Branford, PhD FFSc (RCPA), Jodi Braley, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1890.

https://doi.org/10.1182/blood.V128.22.1890.1890

Published: 2016

Journal Articles

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

David T Yeung, BSc, MBBS, FRACP, FRCPA, Wendy Tara Parker, PhD, Stuart Phillis, B Biotech, Jasmina Georgievski, BSc, Hamish S Scott, BSc, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Susan Branford, PhDFFSc (RCPA)

Blood (2015) 126 (23): 2777.

https://doi.org/10.1182/blood.V126.23.2777.2777

Published: 2015

Journal Articles

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD, Tamara M Leclercq, PhD, Dale Watkins, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Verity A Saunders, BSc (Hons), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 596.

https://doi.org/10.1182/blood.V126.23.596.596

Published: 2015

Journal Articles

RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Deepak Singhal, MD FRCPA, Sophia Hague, BAppSc (MDc), David Roxby, MAppSc AFRCPA FFSc[RCPA], L Amilia Wee, BSc(Hons), Oi-Lin Lee, MBBS, FRCPA, Romi Sinha, MBBS, MIBMS, FACHI, Rakchha Chhetri, MBBS, James X Gray, MBBS, FRACP, FRCPA, MD PhD, Pratyush Giri, MBBS, FRACP, FRCPA, Kathryn Robinson, MBBS, FRACP, FRCPA, Shriram Nath, MBBS, DM, FRCPA, Nicholas Wickham, FRCPA,FRACP,FRCPath, Chi-hung Hui, MBBS, MRCP, FRCPath, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, L Bik To, MBBS, FRACP, FRCPA, PhD, Devendra K Hiwase, MBBS, FRACP, FRCPA, MD PhD

Blood (2015) 126 (23): 3562.

https://doi.org/10.1182/blood.V126.23.3562.3562

Published: 2015

Journal Articles

Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression

Justine E Marum, PhD, Leanne Purins, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Wendy Tara Parker, PhD, David J Price, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, Jasmina Geogievski, BSc, Bradley Chereda, PhD, Andreas Schreiber, PhD, Simon J Tuke, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Susan Branford, PhDFFSc (RCPA)

Blood (2015) 126 (23): 475.

https://doi.org/10.1182/blood.V126.23.475.475

Published: 2015

Journal Articles

Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint

Susan Branford, PhD, David M Ross, MBBS, PhD FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Jodi Braley, Timothy P. Hughes, MD

Blood (2014) 124 (21): 4561.

https://doi.org/10.1182/blood.V124.21.4561.4561

Published: 2014

Journal Articles

KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure

David T Yeung, BSc, MBBS, FRACP, FRCPA, Ljiljana Vidovic, BSc, Carine Tang, BSc., (Hons) PhD, Deborah L White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P Hughes, MD MBBS, FRACP, FRCPA, Agnes S.M. Yong, MD PhD

Blood (2014) 124 (21): 814.

https://doi.org/10.1182/blood.V124.21.814.814

Published: 2014

Journal Articles

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Susan Branford, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Wendy T Parker, PhD, Jodi Braley, John F Seymour, MBBS, FRACP, PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 816.

https://doi.org/10.1182/blood.V124.21.816.816

Published: 2014

Journal Articles

High Plasma Levels of TGF-α and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML

Eva Nievergall, PhD, John Reynolds, PhD, Chung H Kok, PhD, Dale Watkins, PhD, Mark Biondo, PhD, Samantha J Busfield, PhD, Gino Vairo, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, Angel Lopez, PhD, Devendra K Hiwase, MBBS, MD PhD FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD MBBS, FRACP, FRCPA

Blood (2014) 124 (21): 1788.

https://doi.org/10.1182/blood.V124.21.1788.1788

Published: 2014

Journal Articles

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

Wendy T Parker, PhD, Stuart R Phillis, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, David Lawrence, BCS, Andreas Schreiber, PhD, Paul Wang, PhD, Joel Geoghegan, MSc, Stephanie Lustgarten, PhD, Graeme Hodgson, Victor M. Rivera, PhD, Timothy P. Hughes, MD, Hamish Scott, PhD, Susan Branford, PhD

Blood (2014) 124 (21): 399.

https://doi.org/10.1182/blood.V124.21.399.399

Published: 2014

Journal Articles

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Lisa Carne, RN, David Ross, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 1503.

https://doi.org/10.1182/blood.V122.21.1503.1503

Published: 2013

Journal Articles

PCR-Mediated Recombination Can Lead To Artificial Chimera Formation, Which May Pose As BCR-ABL1 Compound Mutations

Wendy T Parker, PhD, Stuart R Phillis, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, Hamish S Scott, PhD, Susan Branford, PhD

Blood (2013) 122 (21): 4014.

https://doi.org/10.1182/blood.V122.21.4014.4014

Published: 2013

Journal Articles

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Haley Altamura, BSc, Nicola Roberts, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Bronte A Jamison, BSc, Chani Field, BSc, Stephanie Lustgarten, PhD, Graeme Hodgson, PhD, Victor M. Rivera, PhD, Timothy P. Hughes, MD, MBBS, Susan Branford, PhD

Blood (2013) 122 (21): 651.

https://doi.org/10.1182/blood.V122.21.651.651

Published: 2013

Journal Articles

The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy

Wendy T Parker, PhD, Alexandra L Yeoman, BSc, Bronte A Jamison, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Hamish S Scott, PhD, Timothy P Hughes, MD, Susan Branford, PhD

Blood (2012) 120 (21): 1692.

https://doi.org/10.1182/blood.V120.21.1692.1692

Published: 2012

Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2012) 120 (21): 165.

https://doi.org/10.1182/blood.V120.21.165.165

Published: 2012

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

NARROW

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR

BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry

Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression

Achieving the Deep Molecular Response Levels Required for an Imatinib Discontinuation Trial Is Strongly Associated with the BCR-ABL Level at the First Qualifying Timepoint

KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

High Plasma Levels of TGF-α and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML

Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

PCR-Mediated Recombination Can Lead To Artificial Chimera Formation, Which May Pose As BCR-ABL1 Compound Mutations

Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome

The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only